Carrington Laboratories Inc. said it has received U.S.Department of Agriculture approval for the use of acemannanas a vaccine adjuvant in poultry. The ACM 1 immune boosterwill be marketed under an exclusive license to Solvay AnimalHealth Inc. in combination with a vaccine for Marek's disease.
The drug, a macrophage stimulant, has been patented by theIrving, Texas, company and is being developed for veterinaryuses as well as for human therapeutics.
Acemannan, isolated from the aloe vera plant, won conditionalUSDA marketing approval for pets in November 1991. It is intesting in a Canadian trial of 40 patients as an adjunct to AZT inAIDS. An interim report on this study should be available byMarch, according to the company.
Carrington stock (AMEX:CRN) closed up 13 cents at $20.13.
(c) 1997 American Health Consultants. All rights reserved.